Ann: Imugene to Present at Annual JPMorgan Healthcare Conference, page-102

Firstly, thank you so much for all your knowledge you have shared with us to give us a better understanding of the anns / data released.

Both CEOs of CHM and IMU want to explore the highest possible dose in their Ph 1 trials as generally more means more. CHMs CEO went even one step further by exploring 2 different highest does scenarios in CHM's trials. What is the highest for 100% safety and what is the highest for acceptable safety. That way Ph 1 trials might take longer as we sh are prepared to wait but LT it will make a huge difference, especially for the CF33 platform.

No sp-firework but considering the red market and some 20c-expectations not met the sp is holding up really well, at least so far.

I hold a few " Non-Hopper " - bios as well and despite great anns those got punished today as well. That way, 12c is a great outcome when it comes to IMU's sp performance history.

Thanks again and I think you deserve a Red Heart too for your HC contributions.

GLTA